Close this search box.

An Update on the Mestinon Clinical Trial

From the desk of Ronald G. Tompkins, MD, ScD
Co-Director, The Harvard ME / CFS Collaboration

Mestinon Trial Update 

In May, 2020, Open Medicine Foundation (OMF) announced the Mestinon Clinical Trial for ME / CFS, conducted at the Brigham & Women’s Hospital by Dr. David Systrom in association with the Harvard ME / CFS Collaboration at the Harvard Affiliated Hospitals.


This study was started after Dr. Systrom observed that some people with ME / CFS have what is known as Preload Failure (PLF).

In this instance, Preload Failure is thought to come from an imbalance in the autonomic nervous system and results in reduced filling of the heart during exertion, and could be associated with postural orthostatic tachycardia syndrome (POTS) and/or post-exertion malaise (PEM).

Prior studies have shown symptomatic improvement in the general population with PLF after treatment with Mestinon.


Dr. Systrom and his research team are now conducting a clinical trial on the therapeutic effects of Mestinon: “The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome.”

To understand the effects of Mestinon, Dr. Systrom utilizes an invasive cardiopulmonary exercise test (iCPET), which measures the blood flow, vascular pressures, and ventilation and gas exchange in the lungs and skeletal muscles during exercise.

In this study, patients perform an iCPET, and take either a 60 mg tablet of Mestinon or placebo, and perform a second iCPET assessment 50 minutes later to assess for any improvement of various exercise parameters.

By investigating the link between the autonomic nervous system and the dynamics of blood flow in people with ME / CFS, we are hopeful that this will lead to new targeted treatments and a deeper understanding of ME / CFS.



If you are able, please consider contributing to our effort to
uncover research-based answers.

Help us improve the quality of life for all sufferers of ME / CFS and other
chronic complex diseases, such as Post Treatment Lyme Disease Syndrome
and Fibromyalgia.



Each CRC arranges its protocols to gather samples, conduct research,
and seek participants if needed. CRCs do not typically solicit participation
or respond to inquiries from the general public.

OMF is not directly involved in the participant selection process; our role is to ensure
that each CRC has the financial resources required to conduct its research.
Thank you for your interest!

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669